Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector

Gene Therapy

Volumn 5, Issue 6, 1998, Pages 809-819

  Herrlinger, U ^a   Kramm, C M ^b   Aboody Guterman, K S ^c   Silver, J S ^d   Ikeda, K ^e   Johnston, K M ^f   Pechan, P A ^g   Earth, R F ^h   Finkelstein, D ⁱ   Chiocca, E A ^a   Louis, D N ^b   Breakefield, X O ^c  

^a Department of Psychology Neurology and Psychiatry   (United States)

^b Neurosurgery   (United States)

^c Pathology Research   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^g MONTREAL GENERAL HOSPITAL   (Canada)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Gene transfer; Glioma; HSV 1; Immunity

Indexed keywords

RIBONUCLEOTIDE REDUCTASE; THYMIDINE KINASE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; GENE TRANSFER; GLIOMA CELL; HERPES SIMPLEX VIRUS 1; IMMUNIZATION; MARKER GENE; NONHUMAN; PRIORITY JOURNAL; RAT; VIRUS IMMUNITY;

ANIMALIA; DNA VIRUSES; HERPES; HUMAN HERPESVIRUS 1;

EID: 7344262312     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300643     Document Type: Article

References (48)

1. Breakefield XO, Kramm C, Chiocca EA, Pechan PA. Herpes simplex virus vectors for tumor therapy. In: Sobol RE, Scanion KJ (eds). The Internet Book of Gene Therapy. Cancer Gene Therapeutics. Appleton & Lange: Stamford, 1995, pp 41-56.
2. Hunter W, Rabkin S, Martuza R. Brain tumor therapy using genetically engineered replication-competent virus. In: Kaplitt MG, Loewy AD (eds). Viral Vectors: Gene Therapy and Neuroscience Applications. Academic Press: San Diego, 1995, pp 259-274.
3. Kramm CM et al. Gene therapy for brain tumors. Brain Palhol 1995; 5: 345-381.
4. Martuza RL et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856.
5. Boviatsis EJ et ni. Long-term survival of rats harbouring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an active thymidine kinase gene. Cancer Res 1994; 54: 5745-5761.
6. Goldstein DJ, Weiler S. Herpes simplex virus type 1-induced ribonucleotide reductase activity is indispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Viral 1988; 62: 196-205.
7. Kramm CM et al. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hi Gene Tlier 1996; 7: 1989-1994.
8. Pyles RB, Thompson RL. Evidence that Herpes simplex virus type 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system. J Virol 1994; 68: 4963-4972.
9. Kramm CM et al. Therapeutic efficiency and safety of a second generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 1997; 8: 2057-2068.
10. Mineta T et al. Attenuated multi-mutated herpes simplex virus1 for the treatment of malignant gliomas. Nature Med 1995; 1: 938-943.
11. Pyles RB et al. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther 1997; 8: 533-544.
12. Baringer JR, Swoveland P. Recovery of Herpes simplex virus from human trigeminal ganglions. Nezv Engl J Med 1973; 288: 648-650.
13. Corey L, Spear PG. Infections with Herpes simplex viruses. Nnv Engl JMed 1986; 314: 686-691.
14. Tzeng J, Earth RF, Grosz CG, James SM. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res 1991; 51: 2373-2378.
15. Rhodes JM, Rasmussen SE, Burchardt S, Larsen SO. Modulation of ß-galactosidase activity in peritoneal macrophages from C57B1 mice after exposure to Propionibacterium acnes. Ada Pathol Microbiol Immunol Scann 1987; 95: 213-220.
16. Rosenberg VVS, Breakefield XO, DeAntonio C, Isacson O. Authentic and artifactual detection of the £. coli lacZ gene product in the rat brain by histochemical methods. Brain Res Mol Brain Res 1992; 16: 311-315.
17. Nahmias AJ et al. Immunology of herpes simplex virus infection: relevance to herpes simplex virus vaccines and cervical cancer. Cancer Res 1976; 36: 826-844.
18. Glorioso JC et al. Identification of herpes simplex virus type l (HSV-1) glycoprotein gC as the immunodominant antigen for HSV-1-specific memory cytotoxic T lymphocytes. J Immunol 1995; 135: 575-582.
19. Para MF, Parish ML, Noble AG, Spear PG. Potent neutralizing activity associated with anti-glycoprotein D specificity among monoclonal antibodies selected for binding to herpes simplex virions. J-Viral 1985; 55: 483-488.
20. Morrison LA, Knipe DM. Immunization with replication defective mutants of Herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol 1994; 68: 689-696.
21. Mester JC, Rouse BT. The mouse model and understanding immunity to herpes simplex virus. Rev Infect Dis 1991; 13 (Suppl. II): S935-S945.
22. Eck SL et al. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Hum Gene Ther 1996; 7: 1465-1482.
23. Martin S, Courtney RJ, Fowler G, Rouse BT. Herpes simplex virus type 1-specific cytotoxic T lymphocytes recognize virus nonstructural proteins. J Virol 1988; 62: 2265-2273.
24. Martin S et al. Murine cytotoxic T lymphocytes specific for herpes simplex virus type 1 recognize the immediate-early protein ICP4 and but not ICPO. J Gen Virol 1990; 71: 2391-2399.
25. Tigges MA et al. Human CDS herpes simplex virus-specific cytotoxic T lymphocyte clones recognize diverse virion protein antigens. J Virol 1992; 66: 1622-1634.
26. Yang Y et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirusinfected hepatocytes in vivo. Gene Therapy 1996; 3: 137-144.
27. Tapscott SJ et al. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Pnc Nail Acad Sei USA 1994; 91: 8185-8189.
28. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after infection of replication-defective adenovirus vectors. Nature Med 1996; 2: 545-550.
29. Brubaker JO et al. Thl-associated immune responses to ßgalactosidase expressed by a replication-defective herpes simplex virus. J Immunol 1996; 157: 1598-1604.
30. Wood MJA et al. Inflammatory effects of gene transfer into the CNS with defective HSV-1 vectors. Gene Therapy 1994; 1: 283291.
31. Barba D, Hardin J, Sadelain M, Gage FH. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Nail Acad Sei USA 1994; 91: 4348-4362.
32. Holladay FP et al. Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary m vitro stimulation with tumor cells. Neurosurgery 1992; 30: 499-504.
33. Tada M, de Tribolet N. Recent advances in immunobiology of brain tumors. J Nenro-Oncol 1993; 17: 261-271.
34. Andreansky S et al. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 1997; 57: 1502-1509.
35. Kobayashi H et al. Specific antigenicity of tumors and immunological tolerance in the rat induced by Friend, Gross and Rauscher viruses. Cancer Res 1973; 33: 1598-1603.
36. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annn Rev Immunol 1995; 13: 399-115.
37. Fraefel C et al. Helper virus-free transfer of Herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 1996; 70: 71907197.
38. Yang Y et al. Cellular immunity to viral antigens limits Eldeleted adenoviruses for gene therapy. Proc Natl Acad Sei USA 1994; 91: 4407-1411.
39. Yang Y, Trinchieri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med 1995; 1: 890-893.
40. Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sei USA 1995; 92: 1401-1405.
41. Davidson el al. A model system for m vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet 1993; 3: 219-223.
42. Kajiwara K et al. Immune responses to adenoviral vectors during gene transfer in the brain. Hum Gene Ther 1997; 8: 253-265.
43. Byrnes AP, MacLaren RE, Charlton HM. Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. J Nenrosci 1996; 16: 30453055.
44. Wood MJA et al. Immune responses to adenovirus vectors in the nervous system. Trends Neurosci 1996; 19: 497-501.
45. Dulbecco R. Production of plaques in monolayer tissue caused by single particles of an animal virus. Proc Natl Acad Sei USA 1952; 38: 747-752.
46. Ko L, Koestner A, Wechsler W. Morphological characterization of nitrosurea-induced glioma cell lines and clones. Ada Neuropath (Berl) 1980; 51: 23-34.
47. Stein GH. T98G: an anchorage-independent human tumor cell line that exhibits stationary phase Gl arrest in vitro. J Cell Physiol 1979; 99: 43-54.
48. Turner DL, Snyder EY, Cepko CL. Lineage-independent determination of cell type in the embryonic mouse retina. Neuron 1990; 4: 833-845.